A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Protocol No

NMDP-CIBMTR-OPTIMIZE

Staff Member

Sameem Abedin

Phase

Summary

The purpose of this study is to see how well a lower dose of cyclophosphamide given after your transplant works to prevent GvHD. The study will also see if the lower dose will decrease the risk for side effects associated with the standard dose of cyclophosphamide.

Objective

A Phase 2 Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis

Study Sites

Froedtert Hospital

Status

OPEN TO ACCRUAL